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Introduction {#sec001}
============

Mycetoma is a tropical chronic granulomatous disease, with the formation of tumor-like soft tissue swelling and the formation of grains \[[@pone.0231871.ref001]\]. This disease usually results from small traumatic implantation of causative agent in subcutaneous tissue mainly located to the foot \[[@pone.0231871.ref002]\]. The disease is responsible of massive distortion, deformities and disabilities, and can be life-threatening if not adequately managed \[[@pone.0231871.ref003]\]. The involved infectious agents are either aerobic filamentous actinomycetes, causing actinomycetoma, or filamentous fungi, causing eumycetoma. Actinomycetoma are commonly caused by *Streptomyces somaliensis* and *Nocardia* spp. while *Madurella mycetomatis* is the commonest agent in eumycetoma \[[@pone.0231871.ref004]--[@pone.0231871.ref006]\].

The treatment of mycetoma cases depends on whether the causative agent is an actinomycete or a fungus. Whereas actinomycetoma are usually adequately treated with antibacterials, eumycetoma show usually a relatively poor response to available antifungal drugs. Therefore, surgery is recommended as the best treatment option of eumycetoma. The surgical treatments ranges from broad surgical excision to limb amputation \[[@pone.0231871.ref007],[@pone.0231871.ref008]\].

Mycetoma was recently added to the WHO list of Neglected Tropical Diseases (NTD) following the Geneva meeting in May 2016. This recognition has brought much more attention to this disease. However, the global burden of mycetoma is still unknown due to the absence of case reporting system \[[@pone.0231871.ref001],[@pone.0231871.ref009]\]. A recent meta-analysis has estimated a mycetoma prevalence up to 1.81 and 3.49 cases per 100,000 habitants in Sudan and Mauritania, respectively \[[@pone.0231871.ref002]\]. Senegal, a country located within the « mycetoma belt » area is burdened with a relatively high mycetoma prevalence. Some studies have described the profile of actinomycetoma and eumycetoma cases diagnosed in the country through cases series a decade ago \[[@pone.0231871.ref010]--[@pone.0231871.ref012]\]. The most recent papers have mainly focused on case reports and have described the epidemiology in a single heath care centre \[[@pone.0231871.ref013],[@pone.0231871.ref014]\]. This study aims to provide updated data on the epidemiology, clinical presentation, laboratory diagnosis, and treatment of mycetoma, based on the patients who had consulted in three health care facilities located in two regions of Senegal.

Materials and methods {#sec002}
=====================

This descriptive, retrospective case series study was carried out between January 2008 and December 2018, in three hospital centres, including Le Dantec university hospital and the Institut d'Hygiene Sociale hospital, which are both located in the capital city Dakar, and the regional hospital of Thies located 70 km East from Dakar. The clinical records of 193 patients with mycetoma who visited the Dermatology wards of these hospitals and/or the orthopaedic ward of Le Dantec hospital, during the study period were thoroughly reviewed.

Mycetoma diagnosis criteria were compatible clinical examination findings (tumor like-swellings, presence of sinus tracts, discharge of pus and/or grains) and, when available, a laboratory diagnosis confirmation.

Clinical diagnosis was mainly based on the colour of the grain and the evolution of the lesion. The microbiological aspects included: 1) the direct microscopic examination of the specimens or the grains, in saline or cotton blue solution after adding 30% potassium hydroxide (KOH), and 2) the culture on both Sabouraud dextrose agar plus chloramphenicol and Lowenstein- Jensen agar. Biopsies have been made in each case for histological examination after Periodic acid--Schiff (PAS), Grocott's methenamine silver (GMS) and hematoxylin and eosin (H&E) staining. X-rays, ultrasound, and CT scan examinations have been performed to investigate severe lesions with bone involvement. At the time of this study, molecular diagnosis was not available at any of the centres. Therefore, species identification could not be confirmed molecularly.

Medical treatment consisted of trimethoprim-sulfamethoxazole, or a combination of trimethoprim-sulfamethoxazole, streptomycin, and amoxicillin/clavulanic acid for actinomycetoma and terbinafine or itraconazole for eumycetoma. In case it was not known if the lesion was an actino- or an eumycetoma, patients were treated with a combination of trimethoprim-sulfamethoxazole, streptomycin, amoxicillin/clavulanic acid and/or itraconazole.

Eumycetoma were also treated surgically. The surgical treatment consisted either in a curative surgical resection of the lesion or a limb amputation in case of bone involvement. Lymphadenopathy surgery consisted of lymph node dissection followed by histopathological examination.

The patients' demographic, place of residency, clinical and biological data were entered into excel table and statistical analysis was performed using TM R2.15.0 software (R Foundation for Statistical Computing, Vienna, Austria). Categorical variables were described as percentages while mean and standard error were used for continuous variables.

Ethical statement {#sec003}
-----------------

This study has been approved by the Ethics Committee of the Cheikh Anta Diop University (Ref number: 0237/2017/CER/UCAD). All the data collected from the study participants have been de-identified. Informed consent was not required as the study consisted in retrospective review of the files of patients who had been diagnosed and treated for mycetoma.

Results {#sec004}
=======

A total of 193 patients diagnosed with mycetoma have been included in this study. The majority of these patients were recruited in Dakar, 108 (55.9%) at Le Dantec hospital, 53 (27.5%) at the Institut d'Hygiène Sociale hospital, and 32 (16.6%) at the Thies regional hospital. The mean age of the patients was 38.3±16.4 years (range: 8--84 years). Most of the patients were 30 years old or more as presented in [Table 1](#pone.0231871.t001){ref-type="table"}; 74.6% of them were male, with a 2.94 male/female ratio ([Table 1](#pone.0231871.t001){ref-type="table"}). Regarding their occupation, 120 (62.1%) were farmers; 22 (11.4%) housewives; 21(10.9%) shopkeeper; and 30 (15.5%) had another occupation, including 7 students and 10 unemployed persons.

10.1371/journal.pone.0231871.t001

###### Demographic data of the study population.

![](pone.0231871.t001){#pone.0231871.t001g}

                           Frequency   \%
  ------------------------ ----------- ------
  **Age distribution**                 
  \< 15 years              4           2.1
  15--30 Years             59          30.6
  30--45 Years             62          32.1
  \> 45 Years              68          35.2
  **Gender**                           
  Male                     144         74.6
  Female                   49          24.4
  Male: Female ratio                   2.94
  **Occupation**                       
  Farmer                   120         62.1
  Housewives               22          11.4
  Street vendor            21          10.9
  Other                    30          15.5
  **Locality of origin**               
  Thiès                    47          24.4
  Dakar                    34          17.6
  Diourbel                 31          16.1
  Louga                    23          11.9
  Saint-Louis              20          10.4
  Matam                    10          5.2
  Kaolack                  6           3.1
  Fatick                   4           2.1
  Kaffrine                 3           1.6
  Sédhiou                  2           1
  Tamba                    2           1
  Kédougou                 1           0.5
  Kolda                    1           0.5
  Nouatchok                1           0.5
  **Type of Mycetoma**                 
  Actinomycetoma           71          36.8
  Eumycetoma               91          47.2
  Undetermined             31          16.1

The geographic distribution across Senegal of the mycetoma cases herein analysed is illustrated in [Table 1](#pone.0231871.t001){ref-type="table"}. Most of the patients originated from the central and northern regions of the country including 47 cases from Thies (24.4%), 31 from Diourbel (16.1%), 23 from Louga (11.9%) and 20 from St Louis (10.4%). Patients originating from the capital city Dakar accounted for 34 cases (17.6%); the remaining patients were distributed in the East and Southern part of Senegal ([Fig 1](#pone.0231871.g001){ref-type="fig"}). The mycetoma cases were classified into three groups according to the type of grains and laboratory criteria: there were 71 (36.8%) actinomycetoma, 91 (47.2%) eumycetoma, and 31 (16.1%) undetermined form ([Table 1](#pone.0231871.t001){ref-type="table"}). Noteworthy, there were more eumycetoma cases in the northern regions than in the other part of the country ([Fig 1](#pone.0231871.g001){ref-type="fig"}).

![Distribution of mycetoma types across Senegal.](pone.0231871.g001){#pone.0231871.g001}

At presentation, the duration of the lesions varied according to cases. The majority of patients 90 (46.6%) had mycetoma for 1 to 5 years while 37 (19.1%) had the infection for more than 10 years ([Table 2](#pone.0231871.t002){ref-type="table"}). In 102 cases (52.8%) the patients experienced pain. In the majority of these patients a painkiller was added to their treatment. The clinical form, the size of the lesion, the type of grains, the anatomical localization (Figs [2](#pone.0231871.g002){ref-type="fig"} and [3](#pone.0231871.g003){ref-type="fig"}), the lymphatic dissemination and the bone lesion are presented in [Table 2](#pone.0231871.t002){ref-type="table"}.

![A dorsolumbar tumoral actinomycetoma cases due to *Actinomadura pelletieri*.](pone.0231871.g002){#pone.0231871.g002}

!["Madura foot" caused by *Actinomadura pelletieri*.](pone.0231871.g003){#pone.0231871.g003}

10.1371/journal.pone.0231871.t002

###### Demographic and clinical findings according to the type of mycetoma.

![](pone.0231871.t002){#pone.0231871.t002g}

                                          Actinomycetoma N = 71   EumycetomaN = 91   Undetermined N = 31   Total N (%)   p-value
  --------------------------------------- ----------------------- ------------------ --------------------- ------------- ----------
  Age in years, mean (SD)                 40.1 (16.3)             35.5 (14.8)        42.5 (19.5)                         0.06
  Male /Female ratio                      2.9                     4.05               1.3                                 
  **Clinical aspects, n (%)**                                                                                            
  **Evolution**                                                                                                          
  \< 1 year                               4(5.7)                  2(2.2)             1(3.2)                7 (3.6)       0.79
  1--5 years                              33(46.5)                40(44)             17(54.9)              90 (46.6)     
  5--10 years                             23(32.3)                29(31.8)           7(22.6)               59 (30.6)     
  10--20 years                            7(9.8)                  16(17.6)           5(16.1)               28 (14.5)     
  \> 20 years                             4(5.7)                  4(4.4)             1(3.2)                9 (4.6)       
  **Presence of pain**                                                                                                   
  Yes                                     41(57.7)                44(48.3)           17(54.9)              102 (52.8)    0.47
  No                                      30(42.3)                47(51.7)           14(45.1)              91 (47.1)     
  **Clinical forms**                                                                                                     
  Tumorous form                           28(39.4)                40(43.9)           14(45.1)              82 (42.5)     0.20
  Inflammatory form                       37(52.1)                41(45.1)           10(32.3)              88 (45.5)     
  Cystic form without grain and fistula   6(8.5)                  10(11)             7(22.6)               23 (11.9)     
  **Size of lesion**                                                                                                     
  \<5 cm                                  0                       1(1.1)             0                     1 (0.5)       0.01
  5--10 cm                                12(17)                  6(6.6)             4(12.9)               22 (11.4)     
  \>10 cm                                 53(74.6)                59(64.8)           17(54.8)              129 (66.8)    
  Undetermined                            6(8,4)                  25(27.5)           10(32.3)              41 (21.2)     
  **Type of grains**                                                                                                     
  Red                                     41 (57.7)               0                  0                     41 (21.2)     \<10^−5^
  Black                                   0                       73 (80.2)          1 (3.3)               74 (38.3)     
  White                                   15 (21.1)               10 (11)            17 (54.9)             42 (21.8)     
  Yellow                                  5 (7.1)                 0                  2 (6.4)               7 (3.6)       
  Absence of grains                       10(14.1)                8(8.8)             11(35.4)              29 (15.1)     
  **Anatomical localization**                                                                                            
  Lower limbs (feet and leg)              65(91.5)                80(88)             31(100)               176 (91.2)    0.28
  Upper Limb (Hand/Arm)                   0                       4(4.3)             0                     4 (2.1)       
  Trunk                                   5(7.1)                  6(6.6)             0                     11 (5.6)      
  Head and Neck                           1(1.4)                  1(1.1)             0                     2 (1.1)       
  **Lymphatic dissemination**                                                                                            
  Yes                                     32 (45.07)              34 (37.3)          6 (19.3)              72 (37.3)     0.01
  No                                      34 (47.8)               37 (40.6)          19 (61.2)             90 (46.6)     
  ND                                      5 (7.04)                20 (21.9)          6 (19.3)              31 (16.1)     
  **Bone lesions**                                                                                                       
  Yes                                     27 (38.02)              41 (45.05)         11 (35.4)             79 (40.9)     0.53
  No                                      44 (61.9)               50 (54.9)          20 (64.5)             114 (59.1)    

Diagnosis of mycetoma was confirmed in 97 cases (50.3%) using microbiological examinations and/or histology. The culture has isolated only 56 species (29%). *Actinomadura pelletieri* was the most isolated species (24) followed by *Madurella mycetomatis* (21), *Falciformispora senegalensis* (5), *Streptomyces somaliensis* (2), *Scedosporum apiospermum* (1), *Penicillium* sp. (1), *Fusarium solani* (1), and *Pseudallescheria boydii (anamorphic*: *Scedosporium boydii/Scedosporium boydii)* (1).

X-Ray examination was done in all the patients and was normal in the majority of cases 114 (59.1%). Bone lesions were identified in 79 patients (40.9%).

At interview, 156 (80.8%) patients have reported history of phytotherapy including 60 cases who have used oral plus local medicinal plants ([Table 3](#pone.0231871.t003){ref-type="table"}), however the nature of the plants used was not mentioned. Mycetoma, clinical cases were treated regarding the type of mycetoma and the availability of the drug. Most of actinomycetoma cases were treated with trimethoprim-sulfamethoxazole, or a combination of trimethoprim-sulfamethoxazole, streptomycin, and amoxicillin/clavulanic acid ([Table 3](#pone.0231871.t003){ref-type="table"}). In eumycetoma cases, itraconazole and terbinafine were used as antifungal agent combined in most cases with surgical treatment as shown in [Table 3](#pone.0231871.t003){ref-type="table"}. Surgical treatment consisted of wide local excision and amputation ([Table 3](#pone.0231871.t003){ref-type="table"}).

10.1371/journal.pone.0231871.t003

###### Treatment and outcome according to the type of mycetoma.
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                                                                        Actinomycetoma N = 71   Eumycetoma N = 91   Undetermined N = 31   Total N (%)   p-value
  --------------------------------------------------------------------- ----------------------- ------------------- --------------------- ------------- ----------
  **Traditional phytotherapy**                                                                                                                          
  Yes                                                                   61(86)                  76(83.5)            19(61.3)              156 (80.8)    0.009
  No                                                                    10(14)                  15(16.5)            12(38.7)              37 (19.2)     
  Local+Oral                                                            21(29.5)                31(34.1)            8(25.8)               60 (31.1)     0.91
  Local                                                                 14(19.7)                14(15.3)            3(9.7)                31 (16.1)     
  Oral                                                                  26(36.6)                31(34.1             8(25.8)               65 (28.5)     
  **Medical treatment**                                                                                                                                 
  Trimethoprim-sulfamethoxazole                                         33(46.5)                0                   12(38.7)              45(23.3)      \<10^−5^
  trimethoprim-sulfamethoxazole + Amox/Ac Clavulanique+ Streptomycine   38(53.5)                0                   4(12.9)               42(21.8)      
  trimethoprim-sulfamethoxazole + Amox/Ac Clavulanique+ Itraconazole    0                       23(25.3)            15(48.4)              38(19.7)      
  Terbinafine                                                           0                       68(74.7)            0                     68(35.2)      
  **Surgery**                                                                                                                                           
  Yes                                                                   9(12.7)                 78(85.7)            13(41.9)              100(51.8)     \<10^−5^
  No                                                                    62(87.3)                13(14.3)            18(58.1)              93(48.2)      
  **Type of surgery**                                                                                                                                   
  Resection                                                             5(7.1)                  43(47.2)            6(19.3)               54(27.9)      0.02
  Amputation                                                            3(4.2)                  35(38.5)            7(22.6)               45(23.3)      
  Lymph node dissection                                                 1(1.4)                  0                   0                     1(0.5)        
  **Outcome**                                                                                                                                           
  Full recovery                                                         30 (42.3)               43 (47.3)           6 (19.4)              79(40.9)      \<10^−5^
  Recurrence                                                            2 (2.8)                 2 (2.2)             3 (9.6)               7(3.7)        
  Lost to follow-up                                                     8 (11.3)                14 (15.4)           12 (38.7)             34(17.6)      
  Ongoing treatment                                                     31 (43.6)               32 (35.1)           10 (32.3)             73(37.8)      

Out of the 33 red-grain actinomycetoma cases treated with trimethoprim-sulfamethoxazole alone, 20 recovered (60.6% cure rate), 4 was lost to follow-up and 9 were still on treatment. Outcome was worse if these red-grain actinomycetoma cases were treated with trimethoprim-sulfamethoxazole + streptomycin + amoxicillin/clavulanic acid as out of the 38 patients, 10 recovered (26.3% cure rate), 2 had a recurrence, 4 was lost to follow-up and 22 were still on treatment.

Out of the white or yellow grain mycetoma cases, treatment with trimethoprim-sulfamethoxazole alone (12 patients) yielded 4 recovery (33.3% cure rate), 1 recurrence, 3 patients lost to follow-up and 4 cases still on treatment. Out of the 4 patients treated with the combination trimethoprim-sulfamethoxazole + streptomycin + amoxicillin/clavulanic acid, 2 was lost to follow-up and 2 were still on treatment. The 15 patients treated with Itraconazole+ antibiotics have presented 2 recovery (13% cure rate), 2 recurrence, 7 lost to follow-up and 4 cases still on treatment.

Out of the 68 black-grain eumycetoma cases treated with terbinafine and surgery, 20 recovered (29.4% cure rate), 2 had a recurrence, 14 were lost to follow-up and 32 were still on treatment. Outcome was better if these black-grain eumycetoma cases were treated with Itraconazole, trimethoprim-sulfamethoxazole + streptomycin + amoxicillin/clavulanic acid and surgery as all the 23 patients recovered (100% cure rate). The patients with eumycetoma cases were treated with terbinafine 500 mg twice daily for 24--48 weeks. In the 20 patients treated with terbinafine who recovered, one patient had a small lesion (less than 5 cm), 4 patients had lesions between 5--10 cm, and 10 patients had lesions larger than 10 cm.

Terbinafine treatment was combined with surgery in 49 of the 68 patients. Among these patients, 31 were treated with surgical removal while 18 were amputated. The 20 patients who recovered had been treated with terbinafine combined with surgery. Ten of them were treated with surgical removal and 10 were amputated. No patient has been cured with terbinafine only.

At the time of survey, 79 (40.9%) patients has presented a full recovery. Only 7(3.7%) patients has presented recurrence ([Table 3](#pone.0231871.t003){ref-type="table"}).

Discussion {#sec005}
==========

With the view of strengthening mycetoma control, it is important to provide accurate and updated epidemiological information in endemic regions. This study provides, for the first time in Senegal, mycetoma cases series diagnosed in three hospital centres located in two different regions and allows an overview of the distribution of clinical cases. The mycetoma prevalence within the study period is underestimated because we have selected only well documented patients to strengthen the disease description.

The patients with mycetoma described in this series were young adults in general with an mean age of 38 years, which is in accordance with previous reports in Senegal and many other countries that have shown the higher frequency of mycetoma between 20 and 40 years of age \[[@pone.0231871.ref011],[@pone.0231871.ref012],[@pone.0231871.ref015],[@pone.0231871.ref016]\]. However, 35.2% of our patients were more than 45 years old. This category of patients was also the most infected group in a series reported in Brazil with an mean age of 48 years \[[@pone.0231871.ref017]\]. The excess of male patients found in this study is in agree with the literature \[[@pone.0231871.ref001],[@pone.0231871.ref003],[@pone.0231871.ref005],[@pone.0231871.ref011]\]. Some authors have suggested the role of hormonal and genetics factors in this elevated male: female ratio \[[@pone.0231871.ref018],[@pone.0231871.ref019]\].

Patients were more frequently diagnosed with eumycetoma (47.2%) than actinomycetoma (37.8%) in our study. In contrast, previous studies in Senegal have reported a relatively higher prevalence of actinomycetoma in their series \[[@pone.0231871.ref011],[@pone.0231871.ref016]\]. This discrepancy might be explained by a recruitment bias because most of these data originated from the Le Dantec hospital dermatology ward where actinomycetoma form are usually managed. However, the predominance of eumycetoma cases in our series is in agree with the findings of Ndiaye *et al*., who have reported 70% eumycetoma *versus* 30% actinomycetoma in Senegal \[[@pone.0231871.ref012]\]. Other reports confirm the relatively high prevalence of eumycetoma in the West-African region \[[@pone.0231871.ref020],[@pone.0231871.ref021]\]. Most of cases in our study were diagnosed based on clinical aspects and grain color. Only half of the cases were confirmed by mycological techniques and histopathology. Indeed, the diagnosis and the confirmation of mycetoma cases is challenging in our resources limited settings. In Senegal, culture and histopathology are the gold standard methods in hospital settings. However, both techniques are operator dependent and need experience which could have its reflections on the accuracy. Many difficulties have been noted in our laboratory settings, including negative culture, the misidentifications of the causative fungal agents and the inability of the technicians to correctly describe the histopathological appearance of mycetoma causative agents. This situation emphasized the need for capacity building of our laboratory technicians on mycetoma diagnosis.

Despite the use of diverse laboratory techniques coupled with clinical findings, the etiological agent remained undetermined in 16% of the patients in our study. This is quite similar to Fahal *et al*., where the etiological agent was undetermined in 13% of their patients \[[@pone.0231871.ref003]\]. The difficulty of identifying the etiological agents can be explained by the lack of adequate diagnostic tools in most of our endemic countries and the impossibility in certain cases to differentiate the causative agents using the available mycological and histological techniques \[[@pone.0231871.ref022],[@pone.0231871.ref023]\]. For example, it is well known that histological features cannot differentiate *Acremonium spp* from *Fusarium spp*, which both produce yellow to white grains with heterogeneous histological aspects \[[@pone.0231871.ref002]\]. The direct nucleotide sequencing in biopsy samples of the 16S rRNA gene, to document actinomycetoma, and the rRNA gene internal transcribed spacer regions, to document eumycetoma, have been proposed to enhance pathogen identification capacities \[[@pone.0231871.ref024]--[@pone.0231871.ref028]\].

The geographical distribution of the patients in our study revealed the predominance of eumycetoma in the Northern region of Senegal and of actinomycetoma in the Central and Southern part of the country is in agreement with previous reports in the country \[[@pone.0231871.ref010]--[@pone.0231871.ref012]\]. This spatial distribution is probably associated with eco-climatic factors, because the dry tropical climate in the North contrasts to the higher annual rainfall in the South. The effect of environmental factors and climate on the distribution of mycetoma cases have been demonstrated in many other countries within the African continent and elsewhere \[[@pone.0231871.ref003],[@pone.0231871.ref015],[@pone.0231871.ref029]--[@pone.0231871.ref031]\]. It is important to note the relatively high number of patients originating from the capital-city Dakar in our study, which is considered as a non-endemic area. One explanation might be the usually protracted incubation lag of the disease; the patients had probably been infected before immigrating to the capital-city. Another likely explanation is that specialized health-care facilities that are capable to manage mycetoma are mainly available in the capital-city.

Patients with mycetoma usually attend the clinic at late stage of the disease \[[@pone.0231871.ref032]\]. Accordingly, most of the times the lag between the disease onset and hospital attendance exceeded 10 years in many of the patients in our study. Most of the patients seen in our study presented with local pain, which is probably associated with an advanced stage of the disease. This late presentation at the hospital can be explained by the lack of capacity among health workers, particularly in rural area, and consequently the absence of health education among patients and \[[@pone.0231871.ref033],[@pone.0231871.ref034]\]. Most of the patients in this study had used of traditional medicine before attending specialized clinics. This is in line with previous reports \[[@pone.0231871.ref035]\].

The clinical presentation was quite similar in both actinomycetoma and eumycetoma; however, bone lesions appeared at an earlier stage in actinomycetoma than in eumycetoma. In this study, most of the lesions was tumor-like, irrespective of the mycetoma type. The lower limbs (feet and leg) were the most affected sites as described in many previous studies \[[@pone.0231871.ref001],[@pone.0231871.ref003],[@pone.0231871.ref011],[@pone.0231871.ref012]\]. However, it is important to note that 37.3% of lesions have spread to the lymph nodes and 40.9% have reached the bones. The frequency of lymphadenopathy is relatively high in this series compared to reports from Sudan (10.3%) or Mexico (1.65%) \[[@pone.0231871.ref001],[@pone.0231871.ref003]\]. It is well known that mycetoma may spread to the lymph nodes particularly in case of multiple inadequate surgery \[[@pone.0231871.ref033],[@pone.0231871.ref036],[@pone.0231871.ref037]\]. Some authors have also demonstrated the possibility of blood borne spread in certain cases. This situation emphasized the need to train surgeons on the management of mycetoma and to highlight that local anaesthesia is contraindicated in mycetoma \[[@pone.0231871.ref007]\].

Most of the mycetoma treatment used in this study is in line with previous published reports. For actinomycetoma, trimethoprim-sulfamethoxazole administrated alone gave better results (60.6% cure rate) compared to the combination of trimethoprim-sulfamethoxazole and the other antibiotics. However, it was difficult to give any conclusion in this last group as most of the patients was still on treatment (trimethoprim-sulfamethoxazole + streptomycin + amoxicillin/clavulanic acid) at the time of this study. Indeed, several studies have shown the excellent clinical response of the combination Co-trimoxazole and Amikacin Sulfate achieving in some studies a cure rate of about 90% \[[@pone.0231871.ref038],[@pone.0231871.ref039]\]. So, this combination remains the recommended treatment for actinomycetoma cases.

For black grain eumycetoma cases, terbinafine was used in the majority of the patients in this series with a low cure rate (29.3%) compared to the excellent response obtained with the combination itraconazole and antibiotics. These results are in line with previous reports showing the low response of eumycetoma to terbinafine. For example, Ndiaye et al have reported 25% cure rate in 23 patients treated with terbinafine \[[@pone.0231871.ref040]\]. However, our study has some limitations as several patients did not completed their follow-up. So, there is a need for further studies to compare the efficacy of these two drugs.

Another big challenge in the control of mycetoma is the management cost particularly in eumycetoma. Treatments are expensive and several patients do not continue their follow up. Therefore, there is a need to find innovative and cost-effective strategies to manage mycetoma cases in our endemic settings.

In conclusion, this study has highlighted the limitations of mycetoma diagnosis in Senegal, the delayed access to healthcare and treatment, and the lack of adequate therapeutic resources. The limitations on fungal species identification is also a challenge as the management and outcome of cases depends on the causative agent. The baseline data provided will contribute to the establishment of a surveillance system for better control and advocate for more resources to fight this devastating disease.

10.1371/journal.pone.0231871.r001
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To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Abdallah M. Samy, PhD

Academic Editor

PLOS ONE

**Additional Editor Comments:**

The authors didn\'t address the previous comments by Reviewer \#2. Please check the decision letter for your revised manuscript sent by PLOS NTDs and address all comments raised by reviewer \#2 (i.e. I added a copy of these comments in this email below). This step is necessary before considering your manuscript for further processing in PLOS ONE. Thanks too much! AMS

Journal Requirements:

When submitting your revision, we need you to address these additional requirements:

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. We note that Figures 1-2 in your submission contain \[map/satellite\] images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: <http://journals.plos.org/plosone/s/licenses-and-copyright>.

We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:

1.    You may seek permission from the original copyright holder of Figures 1-2 to publish the content specifically under the CC BY 4.0 license. 

We recommend that you contact the original copyright holder with the Content Permission Form (<http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf>) and the following text:

"I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (<http://creativecommons.org/licenses/by/4.0/>). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form."

Please upload the completed Content Permission Form or other proof of granted permissions as an \"Other\" file with your submission.

In the figure caption of the copyrighted figure, please include the following text: "Reprinted from \[ref\] under a CC BY license, with permission from \[name of publisher\], original copyright \[original copyright year\]."

2.    If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder's requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

The following resources for replacing copyrighted map figures may be helpful:

USGS National Map Viewer (public domain): <http://viewer.nationalmap.gov/viewer/>

The Gateway to Astronaut Photography of Earth (public domain): <http://eol.jsc.nasa.gov/sseop/clickmap/>

Maps at the CIA (public domain): <https://www.cia.gov/library/publications/the-world-factbook/index.html> and <https://www.cia.gov/library/publications/cia-maps-publications/index.html>

NASA Earth Observatory (public domain): <http://earthobservatory.nasa.gov/>

Landsat: <http://landsat.visibleearth.nasa.gov/>

USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): <http://eros.usgs.gov/#>

Natural Earth (public domain): <http://www.naturalearthdata.com/>

 

**Reviewers\' comments:**

As you describe the new analyses required for acceptance, please consider the following:

**Methods**

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer \#2: The revised manuscript was not there. Only in the marked-up version I saw changes made. This made it difficult to review. I assume that the marked-up version is the revised version.

Line 126: add the following: at the time of this study, molecular diagnosis was not available at any of the centers. Therefore species identification could not be confirmed molecularly.

Line 127: Add: medical treatment consisted of \... or \... for actinomycetoma and \... or \... for eumycetoma. In case it was not known if the lesion was an actino- or an eumycetoma, patients were treated with \... Eumycetoma were also treated surgically.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Results**

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer \#2: Results:the paragraph on the treatment outcome is great but not complete. Could you also tell something on the other treatments and calculate a cure rate. Readers would like to know especially for terbinafine if this is comparable to itraconazole. I know you treated itracanazole in combination with antibiotics, however there is a study from Sudan where this was compared to the classical treatment with itraconazole alone. You could use this in your discussion to speculate what in your patient population was the best terbinafine or itraconazole.

E.g. Out of the x red-grain actinomycetoma cases treated with Bactrim only, ... recovered, ... had a recurrence and .. are still on treatment. Outcome was similar/better/worse if these red-grain actinomycetoma cases were treated with Bactrim + ... as ... recovered, ... had a recurrence and .. are still on treatment. Out of the white or yellow grain actinomycetoma cases ....

Out of the ... black grain eumycetoma cases treated with terbinafin and surgery, ... recovered, ... had a recurrence and .. are still on treatment. Outcome was similar/better/worse if these black-grain actinomycetoma cases were treated with Itraconazole, Bactrim and Clavulanique+ Streptomycine and suergy. For those patients ... recovered, ... had a recurrence and .. are still on treatment.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Conclusions**

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer \#2: Yes. However in the discussion paragraph 284-288 a little bit more discussion is needed on the treatment.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Editorial and Data Presentation Modifications?**

Use  this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend "Minor Revision" or "Accept".

Reviewer \#2: Line 91: actinomycete

Line 95: the surgical treatments range from broad surgical \...

Line 97: this recognition has brought ..

Line 166: In 102 cases (52.8%) the patients experienced pain. In \... of these patients a painkiller was added to their treatment.

Line 183: add to the sentence: At interview, 156 (80.8%) patients have reported history of phytotherapy including 60 cases 186 who have used oral plus local medicinal plants, however the nature of the plants used was not mentioned. Mycetoma, clinical cases were treated ...

Line 189: what is the 100 referring to? I did not see it in the table. Please remove this and say ... most cases with surgical treatment as shown in table 3.

Line 248. You mention that most of the patients presented local pain. Did you give them something to ease the pain? E.g. diclofenac? In the study of Dupont et al. they used diclofenac to ease the pain in an advanced eumycetoma case. They added it to the posaconazole treatment. Unexpectedly, the lesion started healing and the mycetoma disappeared. Did you ever experience this in your patients?

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Summary and General Comments**

Use  this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer \#2: I think it is an important study and needs to be published. However the language still needs polishing up and some adjustments are still needed, especially on the treatment outocome.

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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METHODS

Reviewer \#2: The revised manuscript was not there. Only in the marked-up version I saw changes made. This made it difficult to review. I assume that the marked-up version is the revised version.

Line 126: add the following: at the time of this study, molecular diagnosis was not available at any of the centers. Therefore, species identification could not be confirmed molecularly.

Line 127: Add: medical treatment consisted of \... or \... for actinomycetoma and \... or \... for eumycetoma. In case it was not known if the lesion was an actino- or an eumycetoma, patients were treated with \... Eumycetoma were also treated surgically.

1\. Response: These clarifications have been added in the manuscript as recommended. Line 139 to 148 in the clean revised version

RESULTS

Reviewer \#2: Results: the paragraph on the treatment outcome is great but not complete. Could you also tell something on the other treatments and calculate a cure rate. Readers would like to know especially for terbinafine if this is comparable to itraconazole. I know you treated itracanazole in combination with antibiotics, however there is a study from Sudan where this was compared to the classical treatment with itraconazole alone. You could use this in your discussion to speculate what in your patient population was the best terbinafine or itraconazole.

E.g. Out of the x red-grain actinomycetoma cases treated with Bactrim only, ... recovered, ... had a recurrence and .. are still on treatment. Outcome was similar/better/worse if these red-grain actinomycetoma cases were treated with Bactrim + ... as ... recovered, ... had a recurrence and .. are still on treatment. Out of the white or yellow grain actinomycetoma cases ....

Out of the ... black grain eumycetoma cases treated with terbinafin and surgery, ... recovered, ... had a recurrence and .. are still on treatment. Outcome was similar/better/worse if these black-grain actinomycetoma cases were treated with Itraconazole, Bactrim and Clavulanique+ Streptomycine and suergy. For those patients ... recovered, ... had a recurrence and .. are still on treatment.

2\. Response: This paragraph including the details of treatment and cure rates has been added in the result section as recommended. Line 214 to 231 in the clean revised version

About the discussion to speculate on the best treatment, see response 3.

CONCLUSIONS

Reviewer \#2: Yes. However, in the discussion paragraph 284-288 a little bit more discussion is needed on the treatment.

3\. Response: A paragraph discussing the treatment has been added in the discussion paragraph as recommended, line 324 to 338 in the clean revised version. Three more references have been added in the reference list.

EDITORIAL AND DATA PRESENTATION MODIFICATIONS?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend "Minor Revision" or "Accept".

Reviewer \#2: Line 91: actinomycete

Line 95: the surgical treatments range from broad surgical \...

Line 97: this recognition has brought ..

Line 166: In 102 cases (52.8%) the patients experienced pain. In \... of these patients a painkiller was added to their treatment.

Line 183: add to the sentence: At interview, 156 (80.8%) patients have reported history of phytotherapy including 60 cases 186 who have used oral plus local medicinal plants, however the nature of the plants used was not mentioned. Mycetoma, clinical cases were treated ...

Line 189: what is the 100 referring to? I did not see it in the table. Please remove this and say ... most cases with surgical treatment as shown in table 3.

Line 248. You mention that most of the patients presented local pain. Did you give them something to ease the pain? E.g. diclofenac? In the study of Dupont et al. they used diclofenac to ease the pain in an advanced eumycetoma case. They added it to the posaconazole treatment. Unexpectedly, the lesion started healing and the mycetoma disappeared. Did you ever experience this in your patients?

4\. Response: The above corrections have been made in the manuscript as recommended.

Line 91 (Old version) \<-\> Line 104 (revised version)

Line 95: (Old version) \<-\> Line 107 (revised version)

Line 97: (Old version) \<-\> Line 110 (revised version)

Line 166: (Old version) \<-\> Line 187 (revised version)

Line 183: (Old version) \<-\> Line 205 (revised version)

Line 189: (Old version) \<-\> Line 211 (revised version)

Line 248: About the pain, the patients did not receive diclofenac, they have just used paracetamol.

SUMMARY AND GENERAL COMMENTS

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer \#2: I think it is an important study and needs to be published. However, the language still needs polishing up and some adjustments are still needed, especially on the treatment outcome.

5\. Response: The adjustments on the treatment requested by the reviewer have been done in the results (See response 2). Corrections

JOURNAL REQUIREMENTS:

2\. We note that Figures 1-2 in your submission contain \[map/satellite\] images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: <http://journals.plos.org/plosone/s/licenses-and-copyright>.

We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:

6\. Response: Figures 1-2 have been removed. Data in Fig 1 are presented in table 1. The map (Fig2) showing the distribution of mycetoma types has been replaced by a histogram of the cases in the northern, central and southern of Senegal (New figure 1). Figures 3 and 4 have been renamed Fig 2 and 3.

10.1371/journal.pone.0231871.r004
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Dear Dr. SOW,

We are pleased to inform you that your manuscript,  \"Mycetoma epidemiology, diagnosis management, and outcome in three hospital centres in Senegal from 2008 to 2018\" (PONE-D-20-06483R1), has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Abdallah M. Samy, PhD

Academic Editor

PLOS ONE

Additional Editor Comments:

Please consider the final version attached with this decision letter for production; there are some corrections in the tables. Thanks! AMS
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Dear Dr. Sow:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Abdallah M. Samy

Academic Editor

PLOS ONE
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